Standout Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis 2005 2026 2012 2019 2.9k
  1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2005)
    Paul Rutgeerts, William J. Sandborn et al. New England Journal of Medicine
  2. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease (2010)
    Jean‐Frédéric Colombel, William J. Sandborn et al. New England Journal of Medicine
  3. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2013)
    Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine
  4. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (2013)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  5. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial (2006)
    Jean–Frédéric Colombel, William J. Sandborn et al. Gastroenterology
  6. Crohn's disease (2012)
    Daniel C. Baumgart, William J. Sandborn The Lancet
  7. Ulcerative colitis (2012)
    Íngrid Ordás, Lars Eckmann et al. The Lancet
  8. Inflammatory bowel disease: clinical aspects and established and evolving therapies (2007)
    Daniel C. Baumgart, William J. Sandborn The Lancet
  9. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD (2021)
    Dan Turner, Amanda Ricciuto et al. Gastroenterology
  10. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial (2006)
    Stephen B. Hanauer, William J. Sandborn et al. Gastroenterology
  11. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017)
    William J. Sandborn, Chinyu Su et al. New England Journal of Medicine
  12. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis (2011)
    William J. Sandborn, Gert Van Assche et al. Gastroenterology
  13. A Simple Classification of Crohnʼs Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 (2000)
    Christoph Gasché, Jürgen Schölmerich et al. Inflammatory Bowel Diseases
  14. A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis (2006)
    Geert D’Haens, William J. Sandborn et al. Gastroenterology
  15. Certolizumab Pegol for the Treatment of Crohn's Disease (2007)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  16. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study (2001)
    William A. Faubion, Edward V. Loftus et al. Gastroenterology
  17. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (2012)
    William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine
  18. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial (2007)
    William J. Sandborn, S. B. Hanauer et al. Gut
  19. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis (2019)
    Bruce E. Sands, William J. Sandborn et al. New England Journal of Medicine
  20. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease (2007)
    Stefan Schreiber, Ian C. Lawrance et al. New England Journal of Medicine
  21. Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease (2008)
    Murat Törüner, Edward V. Loftus et al. Gastroenterology
  22. Management of Crohn's Disease in Adults (2009)
    Gary R Lichtenstein, William J. Sandborn et al. The American Journal of Gastroenterology
  23. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab (2007)
    William J. Sandborn, Paul Rutgeerts et al. Annals of Internal Medicine
  24. The Natural History of Adult Crohn's Disease in Population-Based Cohorts (2009)
    Laurent Peyrin‐Biroulet, Edward V. Loftus et al. The American Journal of Gastroenterology
  25. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota (2002)
    David A. Schwartz, Edward V. Loftus et al. Gastroenterology
  26. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial (2001)
    William J. Sandborn, S. B. Hanauer et al. Gastroenterology
  27. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology
  28. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis (2011)
    Jean‐Frédéric Colombel, Paul Rutgeerts et al. Gastroenterology
  29. Natalizumab Induction and Maintenance Therapy for Crohn's Disease (2005)
    William J. Sandborn, Jean‐Frédéric Colombel et al. New England Journal of Medicine
  30. The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients (2003)
    Jean‐Frédéric Colombel, Edward V. Loftus et al. Gastroenterology
  31. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial (2011)
    Walter Reinisch, William J. Sandborn et al. Gut
  32. Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry (2006)
    Gary R. Lichtenstein, Brian G. Feagan et al. Clinical Gastroenterology and Hepatology
  33. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis (2012)
    William J. Sandborn, Subrata Ghosh et al. New England Journal of Medicine
  34. Anti–Interleukin-12 Antibody for Active Crohn's Disease (2004)
    Peter Mannon, Ivan J. Fuss et al. New England Journal of Medicine
  35. A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease (2008)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology
  36. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry (2012)
    Gary R. Lichtenstein, Brian G. Feagan et al. The American Journal of Gastroenterology
  37. The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016)
    Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut
  38. Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort (2010)
    Kelvin T. Thia, William J. Sandborn et al. Gastroenterology
  39. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology
  40. Pouchitis After Ileal Pouch-Anal Anastomosis: A Pouchitis Disease Activity Index (1994)
    William J. Sandborn, William J. Tremaine et al. Mayo Clinic Proceedings
  41. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed (2014)
    Bruce E. Sands, Brian G. Feagan et al. Gastroenterology
  42. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease (2002)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology
  43. A gp130–Src–YAP module links inflammation to epithelial regeneration (2015)
    Koji Taniguchi, Li‐Wha Wu et al. Nature
  44. Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis (2011)
    Alexander C. Ford, William J. Sandborn et al. The American Journal of Gastroenterology
  45. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis (2015)
    Mahmoud Mosli, Guangyong Zou et al. The American Journal of Gastroenterology
  46. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial (2012)
    Paul Rutgeerts, Gert Van Assche et al. Gastroenterology
  47. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011)
    Simon Travis, Dan Schnell et al. Gut
  48. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing (2011)
    Mary V. Relling, William J. Sandborn et al. Clinical Pharmacology & Therapeutics
  49. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial (2013)
    Laurent Peyrin‐Biroulet, Walter Reinisch et al. Gut
  50. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis (2016)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  51. Crohn's disease complicated by strictures: a systematic review (2013)
    Florian Rieder, Ellen M. Zimmermann et al. Gut
  52. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review (2017)
    Mathurin Fumery, Siddharth Singh et al. Clinical Gastroenterology and Hepatology
  53. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis (2021)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  54. Integrin-based therapeutics: biological basis, clinical use and new drugs (2016)
    Klaus Ley, Jesús Rivera–Nieves et al. Nature Reviews Drug Discovery
  55. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions (2015)
    Laurent Peyrin‐Biroulet, Julián Panés et al. Clinical Gastroenterology and Hepatology
  56. Application of Artificial Intelligence to Gastroenterology and Hepatology (2019)
    Catherine Le Berre, William J. Sandborn et al. Gastroenterology
  57. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes (2016)
    Siddharth Singh, Parambir S. Dulai et al. Nature Reviews Gastroenterology & Hepatology
  58. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017)
    Julián Panés, William J. Sandborn et al. Gut
  59. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis (2020)
    Siddharth Singh, M. Hassan Murad et al. Clinical Gastroenterology and Hepatology
  60. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn’s Disease (2018)
    David H. Bruining, Ellen M. Zimmermann et al. Radiology
  61. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis (2019)
    William J. Sandborn, Filip Baert et al. Gastroenterology
  62. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis (2020)
    William J. Sandborn, Subrata Ghosh et al. Gastroenterology
  63. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023)
    William J. Sandborn, Séverine Vermeire et al. The Lancet
  64. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis (2021)
    Siddharth Singh, M. Hassan Murad et al. ˜The œLancet. Gastroenterology & hepatology
  65. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2023)
    Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine
  66. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study (2022)
    William J. Sandborn, Geert D’Haens et al. Gastroenterology

Immediate Impact

5 by Nobel laureates 15 from Science/Nature 180 standout
Sub-graph 1 of 14

Citing Papers

IL-10 constrains sphingolipid metabolism to limit inflammation
2024 StandoutNature
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 Standout
183 intermediate papers

Works of William J. Sandborn being referenced

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 Standout
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
2019 Standout
and 349 more

Author Peers

Author Last Decade Papers Cites
William J. Sandborn 79208 60403 30849 1.4k 103.5k
Paul Rutgeerts 47645 36937 16107 554 63.7k
Jean‐Frédéric Colombel 41043 31226 15887 711 57.3k
Brian G. Feagan 40888 31094 14136 747 52.5k
Séverine Vermeire 34605 25404 12297 1.2k 53.6k
Laurent Peyrin‐Biroulet 32828 24374 12865 1.1k 47.8k
Silvio Danese 28863 20178 12757 1.3k 48.6k
Geert D’Haens 30399 23520 11890 897 41.6k
Stefan Schreiber 25944 17883 10133 870 50.1k
Bruce E. Sands 27560 20316 10502 579 38.2k
Gert Van Assche 26295 20158 10425 445 35.8k

All Works

Loading papers...

Rankless by CCL
2026